Please assess the completion status of the following clinical trial:

Trial Title: Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Participant requires immunoglobulin treatment for primary immunodeficiency disease (PIDD)~2. Participant age is compatible with local package insert requirements~3. Participant has been prescribed or has started treatment with HYQVIA (Immune Globulin (Human) 10% with rHuPH20)~4. Participant is willing and able to comply with the requirements of the protocol.~5. Female participant of child-bearing potential agrees to inform the investigator if she becomes pregnant, or plans to become pregnant during the course of the study~Exclusion Criteria:~1. Participant has known hypersensitivity to any of the components of the medicinal product~2. Participant has participated in an interventional clinical study involving a medicinal product or device within 30 days prior to enrollment or is scheduled to participate in an interventional clinical study involving a medical product or device during the course of this study~3. Participant is a family member or employee of the investigator~4. Participant is planning to become pregnant, pregnant or breastfeeding at the time of enrollment

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HYQVIA- Epoch 1 (Type: None): Participants receiving HYQVIA
- HYQVIA- Epoch 2 (Type: None): Participants with rHuPH antibody titers ≥160 (tested in Epoch 1)

Based on this trial design, predict the completion outcome and termination type (if applicable).